J. Maksimenko

发表

THE ROLE OF GERMLINE BRCA1 FOUNDER MUTATIONS AND SOMATIC TP53 MUTATIONS IN THE TRIPLE-NEGATIVE BREAST CANCER SUBTYPE

J. Maksimenko, 2014 .

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review

J. Gardovskis, G. Purkalne, A. Irmejs, 2018, Hereditary Cancer in Clinical Practice.

Impact of KRAS variant rs61764370 on breast cancer morbidity.

J. Gardovskis, E. Miklasevics, J. Maksimenko, 2015, Experimental oncology.

Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review.

M. Kals, A. Metspalu, N. Tõnisson, 2022, European journal of medical genetics.

Pregnancy after breast cancer in BRCA1/2 mutation carriers

J. Gardovskis, A. Irmejs, J. Maksimenko, 2022, Hereditary cancer in clinical practice.

Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers

J. Gardovskis, G. Trofimovics, G. Purkalne, 2021, Hereditary cancer in clinical practice.

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review

J. Gardovskis, A. Irmejs, S. Subatniece, 2021, Hereditary cancer in clinical practice.

Breast – conserving Surgery in Early – Stage Triple – Negative Breast Cancer: Is There a Higher Risk of Locoregional Recurrence?

A. Irmejs, J. Maksimenko, E. Miklaševičs, 2012 .

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population

J. Gardovskis, G. Purkalne, A. Irmejs, 2018, Hereditary Cancer in Clinical Practice.

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer

J. Gardovskis, I. Melbărde-Gorkusa, JELENA MAKSIMENKO, 2013, Oncology letters.

Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study

F. Cardoso, M. Cardoso, J. Gardovskis, 2022, JMIR formative research.

Body mass index and nipple preservation are major contributors to satisfaction and aesthetic outcome rates after implant-based immediate breast reconstruction

J. Gardovskis, A. Irmejs, J. Maksimenko, 2019, Contemporary oncology.

Penetrance of CHEK2 and BRCA1 Double Heterozygotes in Breast and/or Ovarian Cancer Patients

J. Gardovskis, J. Maksimenko, E. Berga-Švītiņa, 2023, Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences..

Role of Percutaneous Needle Biopsy of Axillary Lymph Nodes to Evaluate Node Positive Breast Cancer after Neoadjuvant Chemotherapy

J. Gardovskis, G. Purkalne, A. Irmejs, 2019, Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences..

Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients

R. Mägi, K. Fischer, B. Vilne, 2023, Cancers.

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population

J. Gardovskis, G. Purkalne, A. Irmejs, 2018, Hereditary cancer in clinical practice.

Evaluation of Breast Skin/Nipple-Areolar Complex Sensation and Quality of Life after Nipple-Sparing Mastectomy Followed by Reconstruction

J. Maksimenko, Jānis Gardovskis, Arvīds Irmejs, 2024, Medicina.